- Home
- TENB vs KRYS Comparison
TENB vs KRYS Comparison
Compare TENB & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENB
- KRYS
- Stock Information
- Founded
- TENB 2002
- KRYS 2015
- Country
- TENB United States
- KRYS United States
- Employees
- TENB N/A
- KRYS N/A
- Industry
- TENB Computer Software: Prepackaged Software
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TENB Technology
- KRYS Health Care
- Exchange
- TENB Nasdaq
- KRYS Nasdaq
- Market Cap
- TENB 4.8B
- KRYS 4.8B
- IPO Year
- TENB 2018
- KRYS 2017
- Fundamental
- Price
- TENB $41.05
- KRYS $164.83
- Analyst Decision
- TENB Buy
- KRYS Strong Buy
- Analyst Count
- TENB 16
- KRYS 7
- Target Price
- TENB $50.40
- KRYS $206.67
- AVG Volume (30 Days)
- TENB 935.0K
- KRYS 309.7K
- Earning Date
- TENB 02-04-2025
- KRYS 11-04-2024
- Dividend Yield
- TENB N/A
- KRYS N/A
- EPS Growth
- TENB N/A
- KRYS N/A
- EPS
- TENB N/A
- KRYS 1.77
- Revenue
- TENB $877,596,000.00
- KRYS $241,519,000.00
- Revenue This Year
- TENB $14.43
- KRYS $485.65
- Revenue Next Year
- TENB $9.64
- KRYS $58.64
- P/E Ratio
- TENB N/A
- KRYS $92.96
- Revenue Growth
- TENB 13.97
- KRYS 2722.80
- 52 Week Low
- TENB $35.25
- KRYS $107.50
- 52 Week High
- TENB $53.50
- KRYS $219.34
- Technical
- Relative Strength Index (RSI)
- TENB 45.37
- KRYS 40.33
- Support Level
- TENB $39.63
- KRYS $155.16
- Resistance Level
- TENB $42.95
- KRYS $176.59
- Average True Range (ATR)
- TENB 1.24
- KRYS 9.47
- MACD
- TENB -0.26
- KRYS -2.78
- Stochastic Oscillator
- TENB 33.33
- KRYS 23.79
About TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.